Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies
Transplantation of a CD3/CD19 depleted stem cell grafts after dose reduced conditioning for
the treatment of treatment refractory or relapsed hematologic malignancies after preceding
allogeneic or autologous hematopoietic cell transplantation.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Wolfgang A Bethge, MD
University of Tuebingen Medical Center
Germany: Federal Institute for Drugs and Medical Devices